Over the last 8 years, the FDA has granted accelerated approval to multiple new agents in relapsed/refractory DLBCL including polatuzumab in combination with rituximab-bendamustine [4], selinexor [5], tafasitamab with lenalidomide [6], loncastuximab tesirine-lpyl [7], brentuximab vedotin with lenalidomide + rituximab [8], and multiple CD19 chimeric antigen receptor (CAR) T-cell therapy options and bispecific antibodies (BsAbs) [9,10,11,12,13] (Figure 1). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.